Effect of Nickel and Titanium on DNA Methylation in Human Gingival fibroblast cells In Vitro

Metallic dental materials are frequently used in clinics. Cytotoxicity and allergy tests in vitro and in vivo have primarily been used to evaluate their safety. However, whether these dental materials cause genetic modifications leading to pathological conditions in oral tissues has not been shown. Gene mutations and epigenetic alterations are the initial steps of genetic modification. Environmental factors, including chemical components and mechanical stimulations, can cause epigenetic modifications that are often involved in pathogenic changes in humans. Therefore, we hypothesize that dental materials induce specific alterations in DNA methylation. This study aims to demonstrate specific alterations in DNA methylations in human gingival fibroblast cells (HGnF) induced by metal components (Ni and Ti ) of dental materials. The mRNA expression level of IL−6 for 2 weeks was significantly higher in the HGnF cells treated with 50 μM of Ni and 10 μM of Ti compared to the controls. Quantitative methylation − specific PCR ( qMSP) revealed that the DNA methylation percentage levels of IL−6 and IFN−γ in HGnF cells treated with 10 μM of Ti for 2 weeks were significantly lower compared to the controls. In conclusion, this study found hypomethylation of IL−6 and IFN−γ, followed by their upregulated expressions in HGnF cells stimulated with Ti. Methylation levels may serve as a new cytotoxic assessment tool, even for biocompatible materials.departmental bulletin pape

Prevalence, genetic characteristics, and antimicrobial resistance of staphylococcal isolates from oral cavity and skin surface of healthy individuals in northern Japan

Background: Oral cavity is an ecological niche for colonization of staphylococci, which are a major bacterial species causing community-acquired infections in humans. In this study, prevalence, and characteristics of staphylococci in oral cavity and skin of healthy individuals were investigated in northern Japan. Methods: Saliva from oral cavity and swab from skin surface of hand were collected and cultured on selective media. Species of the isolates were identified genetically, and ST was determined for S. aureus and S. argenteus. Genes associated with antimicrobial resistance were detected by PCR. Results: Among 166 participants, a total of 75 S. aureus isolates were obtained from 61 individuals (37 %), and recovered more frequently in oral cavity (n = 48) than skin (n = 27). Among 23 STs identified in S. aureus isolates, ST8 (CC8), ST15 (CC15), and ST188 (CC1) were the most common (10 isolates each), with STs of CC1 being dominant (17 isolates). Methicillin-resistant S. aureus (MRSA) was isolated in the skin of two individuals and belonged to ST1 and ST6. Resistance to erythromycin and gentamicin associated with erm(A) and aac(6’)-Ie-aph(2”)-Ia, respectively, was more commonly found in ST5 and ST8 isolates. One S. argenteus isolate (ST2250, mecA-negative) was recovered from oral cavity of a participant (0.6 %). A total of 186 isolates of coagulase-negative staphylococci (CoNS) were recovered from 102 participants and identified into 14 species, with S. warneri being the most common (n = 52), followed by S. capitis (n = 42), S. saprophyticus (n = 20) and S. haemolyticus (n = 19). mecA was detected in S. saprophyticus, S. haemolyticus, and S. caprae, while arginine-catabolic mobile element (ACME) in only S. capitis and S. epidermidis. Conclusion: S. aureus was more prevalent in oral cavity than skin surface, belonging to three major STs, with CC1 being a dominant lineage. The prevalence of antimicrobial resistance was distinct depending on CoNS species

Nanometer-Size Effect on Hydrogen Sites in Palladium Lattice

Nanometer-sized materials attract much attention because their physical and chemical properties are substantially different from those of bulk materials owing to their size and surface effects. In this work, neutron powder diffraction experiments on the nanoparticles of palladium hydride, which is the most popular metal hydride, have been performed at 300, 150, and 44 K to investigate the positions of the hydrogen atoms in the face-centered cubic (fcc) lattice of palladium. We used high-quality PdD_0.363 nanocrystals with a diameter of 8.0 ± 0.9 nm. The Rietveld analysis revealed that 30% of D atoms are located at the tetrahedral (T) sites and 70% at the octahedral (O) sites. In contrast, only the O sites are occupied in bulk palladium hydride and in most fcc metal hydrides. The temperature dependence of the T-site occupancy suggested that the T-sites are occupied only in a limited part, probably in the subsurface region, of the nanoparticles. This is the first study to determine the hydrogen sites in metal nanoparticles

Empagliflozin in Patients with Chronic Kidney Disease

Background The effects of empagliflozin in patients with chronic kidney disease who are at risk for disease progression are not well understood. The EMPA-KIDNEY trial was designed to assess the effects of treatment with empagliflozin in a broad range of such patients. Methods We enrolled patients with chronic kidney disease who had an estimated glomerular filtration rate (eGFR) of at least 20 but less than 45 ml per minute per 1.73 m(2) of body-surface area, or who had an eGFR of at least 45 but less than 90 ml per minute per 1.73 m(2) with a urinary albumin-to-creatinine ratio (with albumin measured in milligrams and creatinine measured in grams) of at least 200. Patients were randomly assigned to receive empagliflozin (10 mg once daily) or matching placebo. The primary outcome was a composite of progression of kidney disease (defined as end-stage kidney disease, a sustained decrease in eGFR to < 10 ml per minute per 1.73 m(2), a sustained decrease in eGFR of & GE;40% from baseline, or death from renal causes) or death from cardiovascular causes. Results A total of 6609 patients underwent randomization. During a median of 2.0 years of follow-up, progression of kidney disease or death from cardiovascular causes occurred in 432 of 3304 patients (13.1%) in the empagliflozin group and in 558 of 3305 patients (16.9%) in the placebo group (hazard ratio, 0.72; 95% confidence interval [CI], 0.64 to 0.82; P < 0.001). Results were consistent among patients with or without diabetes and across subgroups defined according to eGFR ranges. The rate of hospitalization from any cause was lower in the empagliflozin group than in the placebo group (hazard ratio, 0.86; 95% CI, 0.78 to 0.95; P=0.003), but there were no significant between-group differences with respect to the composite outcome of hospitalization for heart failure or death from cardiovascular causes (which occurred in 4.0% in the empagliflozin group and 4.6% in the placebo group) or death from any cause (in 4.5% and 5.1%, respectively). The rates of serious adverse events were similar in the two groups. Conclusions Among a wide range of patients with chronic kidney disease who were at risk for disease progression, empagliflozin therapy led to a lower risk of progression of kidney disease or death from cardiovascular causes than placebo